Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-11
2006-07-11
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
07074756
ABSTRACT:
Although it is known that adiponectin, which is adipose-specific protein, has effects of suppressing the proliferation and migration of vascular smooth muscle, an effect against arteriosclerosis, an effect of inhibiting the activation of monocytes and macrophages and an anti-inflammatory effect, its action on hepatic stellate cells has never been known hitherto. The present invention has elucidated that adiponectin inhibits the actions of TGFB and PDGF on hepatic stellate cells and thereby exerts effects of suppressing hepatic fibrosis and promoting the proliferation of normal hepatocytes.
REFERENCES:
patent: 2000-256208 (2000-09-01), None
patent: 2000-336040 (2000-12-01), None
patent: 02/072149 (2002-09-01), None
Y. Arita et al., “Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity”, Biochemical and Biophysical Research Communications, vol. 257, 1999, pp. 79-83.
S. Kihara, “Adiponectin”, Hormon & Clinic, Apr. 1, 2001, vol. 49, No. 4, pp. 9-15, with full English translation.
Y. Matsuzawa et al., “Molecular mechanism of Metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances”, Annals of the New York Academy of Sciences, vol. 892, 1999, pp. 146-154.
T. Yokota et al., “Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages”, Blood, vol. 96, No. 5, 2000, pp. 1723-1732.
M. Yoda-Murakami et al., “Change in expression of GBP28/adioponectin in carbon tetrachloride-administrated mouse liver”, Biochemical and Biophysical Research Communications, vol. 285, No. 2, Jul. 13, 2001, pp. 372-377.
K. Maeda et al., “cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1 (Adipose Most Abundant Gene Transceipt 1)”, Biochemical and Biophysical, Research Communications, vol. 221, 1996, pp. 286-289.
Y. Artia et al., “Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity”, Biochemical and Biophysical Research Communications, vol. 257, pp. 79-83, (1999).
Kihara et al., “Anti-atherogenic property of adipocyte-derived plasma protein, adiponectin”. BIOSIS, 2001, XP00297211, abstract.
Ouchi et al., “Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages”, Circulation, American Heart Association, Texas, U.S. vol. 103, No. 8, pp. 1057-1063. Feb. 2001, XP002970251.
N. Kihara, “Adiponectin, Hormone to Rinsho”, Apr. 1, 2001, vol. 49, No. 4, pp. 9-15.
Funahashi Tohru
Matsuzawa Yuji
Tamura Shinji
Sankyo Company Limited
Tsay Marsha
Weber Jon
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Liver generation promoter does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liver generation promoter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liver generation promoter will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602537